Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013 Jun;40(6):831-41. doi: 10.3899/jrheum.120572. Epub 2013 Apr 15.
Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):150-4.
Clarke AE, Urowitz MB, Monga N, Hanly JG Costs associated with severe and nonsevere systemic lupus erythematosus in Canada. Arthritis Care Res (Hoboken). 2015 Mar;67(3):431-6. doi: 10.1002/acr.22452.
Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, Sylvestre MP Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012 Jul;71(7):1128-33. doi: 10.1136/annrheumdis-2011-200702. Epub 2012 Jan 12.
Haase KR, Loiselle CG Oncology team members' perceptions of a virtual navigation tool for cancer patients. Int J Med Inform. 2012 Jun;81(6):395-403. doi: 10.1016/j.ijmedinf.2011.11.001. Epub 2012 Jan 13.
Isenberg DA, Gladman D The Systemic Lupus International Collaborating Clinics Group--origins and outcomes. Lupus. 2001;10(5):375-7.
Isenberg DA, Ramsey-Goldman R, Gladman D, Hanly JG The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today. Lupus. 2011 Nov;20(13):1426-32. doi: 10.1177/0961203311421501. Erratum in: Lupus. 2012 Jan;21(1):114.
Lee J, Dhillon N, Pope J All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. Rheumatology (Oxford). 2013 May;52(5):905-9. doi: 10.1093/rheumatology/kes391. Epub 2013 Jan 9.
Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002 May;61(5):409-13.
Neville C, DaCosta D, Rochon M, Eng D, Fortin PR Toward the development of a lupus interactive navigator to facilitate patients and their health care providers in the management of lupus: results of web-based surveys. JMIR Res Protoc. 2014 Dec 22;3(4):e65. doi: 10.2196/resprot.3349.
Petri M, Genovese M, Engle E, Hochberg M Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 Aug;34(8):937-44.
Steiner JF, Koepsell TD, Fihn SD, Inui TS A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988 Aug;26(8):814-23.
Sun X, Li X, Chen C, Song Y A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint. J Biopharm Stat. 2013;23(5):986-1003. doi: 10.1080/10543406.2013.813524.
Sylvestre MP, Abrahamowicz M Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med. 2009 Nov 30;28(27):3437-53. doi: 10.1002/sim.3701.
Telek HH, Yesilirmak N, Sungur G, Ozdemir Y, Yesil NK, Ornek F Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis. Doc Ophthalmol. 2017 Dec;135(3):187-194. doi: 10.1007/s10633-017-9607-9.
Waldron N, Brown S, Hewlett S, Elliott B, McHugh N, McCabe C 'It's more scary not to know': a qualitative study exploring the information needs of patients with systemic lupus erythematosus at the time of diagnosis. Musculoskeletal Care. 2011 Dec;9(4):22
Ward MM, Marx AS, Barry NN Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000 Mar;27(3):664-70.
Wynant W, Abrahamowicz M Flexible estimation of survival curves conditional on non-linear and time-dependent predictor effects. Stat Med. 2016 Feb 20;35(4):553-65. doi: 10.1002/sim.6740. Epub 2015 Nov 6.
Wynant W, Abrahamowicz M Impact of the model-building strategy on inference about nonlinear and time-dependent covariate effects in survival analysis. Stat Med. 2014 Aug 30;33(19):3318-37. doi: 10.1002/sim.6178. Epub 2014 Apr 22.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
